GLP-1 medication can help you lose weight, but its just one part of the picture
At week 68, 8689% of patients without T2D achieved 5% body weight loss (STEP 1, 3 and 4), with 69% of patients with T2D achieving this threshold (STEP 2)
Semaglutide is an investigational GLP-1 receptor agonist peptide that has been widely studied for its effects on glucose regulation, insulin secretion, appetite, and metabolic pathways involved in body weight management
A comprehensive review of free radicals, oxidative stress, and antioxidants: overview, clinical applications, global perspectives, future directions, and mechanisms of antioxidant activity of flavonoid compounds
The platform is committed to expanding access as broadly as possible while maintaining full regulatory compliance